Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	20152
Country	Italy

Received	2015-05-29 16:06
Peer-Review Started	2015-05-30 09:06
To Make the First Decision	2015-06-18 15:35
Return for Revision	2015-06-26 15:34
Revised	2015-08-18 05:03
Second Decision	2015-11-06 17:53
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-11-25 16:38
Articles in Press	2015-11-25 16:39
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-01-09 22:08
Publish the Manuscript Online	2016-01-14 20:17

ISSN	1948-5204 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Review
Article Title	State of the art biological therapies in pancreatic cancer
Manuscript Source	Invited Manuscript
All Author List	Mariacristina Di Marco, Elisa Grassi, Sandra Durante, Silvia Vecchiarelli, Andrea Palloni, Marina Macchini, Riccardo Casadei, Claudio Ricci, Riccardo Panzacchi, Donatella Santini and Guido Biasco
Funding Agency and Grant Number
Corresponding Author	Elisa Grassi, MD, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Sant’Orsola-Malpighi Hospital, Massarenti Street 11, 40138 Bologna, Italy. elisa.grax@gmail.com
Key Words	Pancreatic cancer; Molecular characterization; Targeted therapy; Epidermal growth factor receptor inhibitors; Embryonic pathway inhibitors; Antiangiogenic therapies
Core Tip	Our study aims to give an overview of the progress made in molecular targeted therapy for pancreatic cancer in recent years and the current status of clinical trials in the field. Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with a five-year survival rate of approximately 5%. Several target agents have been tested in PDAC but almost all have failed to demonstrate efficacy in late phase clinical trials, even with a better understanding of PDAC molecular biology generated by large cancer sequencing initiatives in the past decade. Eroltinib (small-molecule tyrosine-kinase inhibitor of epidermal growth factor receptor) plus gemcitabine is actually the only schedule with a biological agent approved for advanced pancreatic cancer, but it resulted in a very modest survival benefit in unselected patients. In our work, we reported a summary of the main clinical trials (close and ongoing) that refer to biological therapy evaluation in pancreatic cancer treatment.
Publish Date	2016-01-14 20:17
Citation	Di Marco M, Grassi E, Durante S, Vecchiarelli S, Palloni A, Macchini M, Casadei R, Ricci C, Panzacchi R, Santini D, Biasco G. State of the art biological therapies in pancreatic cancer. World J Gastrointest Oncol 2016; 8(1): 55-66
URL	http://www.wjgnet.com/1948-5204/full/v8/i1/55.htm
DOI	http://dx.doi.org/10.4251/wjgo.v8.i1.55

Full Article (PDF)	WJGO-8-55.pdf
Full Article (Word)	WJGO-8-55.doc
Manuscript File	20152-Review.docx
Answering Reviewers	20152-Answering reviewers.pdf
Audio Core Tip	20152-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	20152-Conflict-of-interest statement.pdf
Copyright License Agreement	20152-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	20152-Language certificate.pdf
Peer-review Report	20152-Peer-review(s).pdf
Scientific Misconduct Check	20152-Scientific misconduct check.pdf
Scientific Editor Work List	20152-Scientific editor work list.pdf